Antiglobulin sera from nine different manufacturers have been tested, over a two-year period, for their ability to detect the complement components beta 1A, alpha 2D, and beta 1E. The results demontrate considerable variation in the abilities of sera from different manufacturers to detect these components and indicate that not all sera on the market are suitable reagents for diagnostic use and compatibility tests. The results also show that there is considerable variation between different lots of serum from some of the manufacturers. In general, the anti-complement levels of these reagents have increased during the two-year period of study but not all companies produce suitable reagents for routine use.

Antibodies, Anti-Idiotypic↗

PubMedDate not supplied

Evaluation of commercial antiglobulin sera over a two-year period. Part II. Anti-IgG and anti-IgM levels and undesirable contaminating antibodies.

Antiglobulin sera, from nine different manufacturers, have been tested over a two-year period for their ability to detect different nonagglutinating, IgG and IgM blood group antibodies and for the presence of undesirable antibodies that cause the agglutination of nonglobulin coated red blood cells. There are not so many differences in anti-IgG levels among the sera as there are differences in anticomplement levels. Over the two-year period, there have been, in general, increases in the amounts of anti-IgM antibodies in the sera tested. Several of the sera, apparently prepared by dilution of raw rabbit serum and not by adsorption, contain antibodies that cause the agglutination of red blood cells not coated with IgG, IgM, or any of the components of complement.

Agglutinins↗

PubMedDate not supplied

Studies on the blood of an MiV homozygote.

An individual, whose parents are third cousins, has been shown to be homozygous for the rare Mi.V. condition. The proposita's red blood cells type as M-, N+(weak), S-, s+(strong), U+, Mi(a-), Vw-, Hil+; Wr(a-b-). The cells react, albeit less strongly than most other samples, with anti-Ena. However, from studies on the red blood cells of the proposita and on those of another person of the En(a+), Wr(a-b-) phenotype, it is apparent that the term "anti-Ena" actually describes a number of antibodies of differing specificities. Inhibition studies with sialoglycoprotein (SGP) isolates, and tests on protease-modified red blood cells illustrate some of the differences in specificity. Biochemical analyses of the SGPs of the red blood cells of the MiV homozygote and those of her parents confirm that the Mi.V condition is associated with the absence of normal MN SGP (alpha) and normal Ss SGP (delta), the appearance of a hybrid SGP molecule comprised of a portion of the MN SGP at its NH2 terminal end, and a portion of the Ss SGP at its C terminal end.

Animals↗

PubMedDate not supplied

Another individual (J.R.) whose red blood cells appear to carry a hybrid MNSs sialoglycoprotein.

The serum of J.R. contains anti-Wrb and her red blood cells are of the phenotype Wr(a-b-). Evidence was obtained that suggested that her cells totally lack normal MN and Ss sialoglycoproteins (SGPs), and carry instead an abnormal SGP, which is likely to be a hybrid SGP resembling the MN SGP in its outer portion and the Ss SGP in its inner portion. Although the apparent hybrid SGPs of J.R. and the MiV homozygote are virtually indistinguishable in terms of their electrophoretic mobility (apparent molecular weight 40,000) and staining characteristics, they are not identical. That of J.R. is associated with a weak M and increased S antigen, while that of the MiV homozygote is associated with a very weak N, a greatly exalted s, and the rare antigen, Hil. Like the study on the blood of the MiV homozygote, serologic studies on the red blood cells of J.R. have revealed considerable heterogeneity of what have previously been called the Ena antigen and anti-Ena antibodies.

Adsorption↗